Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms

被引:15
|
作者
Couce, ME [1 ]
Bautista, D [1 ]
Costa, J [1 ]
Carter, D [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
关键词
lung carcinoid; neuroendocrine; p53; K-ras; N-ras; H-ras;
D O I
10.1097/00019606-199906000-00003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study screened 11 samples of typical carcinoid (TC), 4 samples of atypical carcinoid (AC), 1 sample of large cell neuroendocrine carcinoma (LCNEC), and four metastases for point mutations in exons 5 to 8 of the p53 gene, and exons 1 and 2 of the K-ras, H-vas, and N-ras genes using polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) and direct sequencing and by immunohistochemistry for p53. Exon 1 of K-ras was mutated in two samples of low-grade AC and a metastasis from one of these tumors (GAT12 and AGT12, respectively). No mutations in N-ras or H-ras were found. Mutations in exons 5 and 8 of the p53 gene were identified in a high-grade AC and a LCNEC. Positive immunostaining for p53 was present in three samples, with only one genotypic mutation shown (LCNEC). In conclusion, point mutations of the p53 gene were infrequent in these pulmonary neuroendocrine tumors, did not correlate in all samples with immunostaining, and were associated with the higher-grade tumors. Second, the presence of K-rns mutations seems to be associated with the higher-grade carcinomas. Third, N-ras and H-ras mutations were not found with these pulmonary neuroendocrine tumors.
引用
收藏
页码:71 / 79
页数:9
相关论文
共 50 条
  • [1] Analysis of K-ras, N-ras, H-ras and p53 in lung neuroendocrine neoplasms. Can we predict prognosis?
    Couce, ME
    Bautista, D
    Costa, J
    Carter, D
    [J]. LABORATORY INVESTIGATION, 1997, 76 (01) : 951 - 951
  • [2] N-RAS, H-RAS, AND K-RAS - A DIFFERENCE IN TRANSFORMING POTENTIAL
    MAHER, J
    BAKER, DA
    DIBB, NJ
    ROBERTS, IAG
    [J]. BLOOD, 1994, 84 (10) : A295 - A295
  • [3] H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers
    Przybojewska, B
    Jagiello, A
    Jalmuzna, P
    [J]. CANCER GENETICS AND CYTOGENETICS, 2000, 121 (01) : 73 - 77
  • [4] ANALYSIS OF H-RAS, K-RAS AND N-RAS GENES FOR EXPRESSION, MUTATION AND AMPLIFICATION IN LARYNGEAL TUMORS
    KIARIS, H
    SPANDIDOS, DA
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (01) : 75 - 80
  • [5] EVIDENCE FOR CELL-SPECIFIC DIFFERENCES IN TRANSFORMATION BY N-RAS, H-RAS AND K-RAS
    MAHER, J
    BAKER, DA
    MANNING, M
    DIBB, NJ
    ROBERTS, IAG
    [J]. ONCOGENE, 1995, 11 (08) : 1639 - 1647
  • [6] Mutation and expression analysis of K-Ras, H-Ras, N-Ras and B-Raf oncogenes in Wilms tumors
    Dalpa, Efterpi
    Gourvas, Victor
    Soulitzis, Nikolaos
    Spandidos, Demetrios A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S93 - S93
  • [7] Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients
    Malgorzata Banys-Paluchowski
    Karin Milde-Langosch
    Tanja Fehm
    Isabell Witzel
    Leticia Oliveira-Ferrer
    Barbara Schmalfeldt
    Volkmar Müller
    [J]. Breast Cancer Research and Treatment, 2020, 179 : 403 - 414
  • [8] Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors
    Vageli, D
    Kiaris, H
    Delakas, D
    Anezinis, P
    Cranidis, A
    Spandidos, DA
    [J]. CANCER LETTERS, 1996, 107 (02) : 241 - 247
  • [9] The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants
    Parker, Jillian A.
    Mattos, Carla
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (08):
  • [10] Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients
    Banys-Paluchowski, Malgorzata
    Milde-Langosch, Karin
    Fehm, Tanja
    Witzel, Isabell
    Oliveira-Ferrer, Leticia
    Schmalfeldt, Barbara
    Mueller, Volkmar
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 403 - 414